HRD1 attenuates the high uptake of [F]FDG in hepatocellular carcinoma PET imaging.

INTRODUCTION

Due to individual deviations in tumor tissue uptake, the role of [F]fluorodeoxyglucose ([F]FDG) positron emission tomography (PET) in hepatocellular carcinoma (HCC) diagnosis is limited. β-Hydroxy β-methylglutaryl-CoA reductase degradation 1 (HRD1) plays a key role in clearing misfolded proteins. This study is aimed to investigate the role and mechanism of HRD1 in [F]FDG uptake for the diagnosis of HCC.

METHODS

HRD1 expression level was detected using immunohistochemical (IHC) staining in 9 HCC patients. [F]FDG PET/CT scans were conducted before treatment. [F]FDG uptakes in HRD1 overexpressed and knockdown transgenic models were measured by γ-counter and microPET imaging. The GLUT1-HRD1 complex was examined by co-immunoprecipitation and IHC assays. GLUT1 expression in different cell lines, xenograft models and HCC patients was evaluated by Western blot and IHC assays.

RESULTS

HRD1 was highly expressed in the HCC tumors of patients with low [F]FDG uptake, while the HRD1 expression was obviously low in the higher [F]FDG uptake group. Both in vitro and in vivo studies found that HRD1 significantly inhibited [F]FDG uptake in HCC Huh7 cell lines and animal models. Furthermore, the co-location and interaction of HRD1 with GLUT1 were detected, and the results also indicate that HRD1 could induce the degradation of GLUT1 in vitro and in vivo.

CONCLUSION

HRD1 inhibits the high uptake of [F]FDG in HCC tumor cells by inducing degradation of GLUT1, which leads to decreased diagnostic efficiency of [F]FDG PET imaging for HCC.

ADVANCES IN KNOWLEDGE

This study suggests that HRD1 inhibits the high uptake of [F]FDG in HCC tumor by inducing degradation of GLUT1.

IMPLICATIONS FOR PATIENT CARE

HCC diagnosis with [F]FDG PET should be accompanied by determination of HRD1 expression, and patients with high tumor HRD1 expression might be unsuitable for [F]FDG PET.